This stock is no longer traded. It was delisted on July 21, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, particularly in neuromuscular, neurological, and metabolic areas. Its primary products include FIRDAPSE (amifampridine phosphate), approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS); AGAMREE (vamorolone), a corticosteroid for Duchenne muscular dystrophy; and FYCOMPA (perampanel), used for focal onset seizures and tonic-clonic seizures. The company emphasizes patient accessibility through comprehensive support services, patient advocacy, and community-building initiatives to ensure seamless treatment access. Catalyst Pharmaceuticals Inc. maintains a strong U.S. commercial presence while pursuing strategic partnerships for global expansion. Guided by core values of passion, trust, and integrity, it prioritizes ethical standards and innovative therapies addressing unmet needs in small patient populations. Founded and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals Inc. plays a vital role in the rare disease sector by delivering targeted treatments that improve patient outcomes.
Website355 Alhambra Circle
Coral Gables, FL, 33134
United States
Summary of May 11's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Summary of Oct 5's posts. Generated by AI.
Summary of Jan 10's posts. Generated by AI.
Investors talking about CPRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.